About Stallergenes

Key figures

International leader in allergen immunotherapy

  • Nearly 500 000 patients are treated yearly by Stallergenes
  • Nearly 1000 men and women are employed by Stallergenes throughout the world.
  • Stallergenes dedicates 20% (gross) of its 2010 sales to the research and development for better therapeutic solutions.  
  • Stallergenes has initiated and conducted nearly 30 controlled clinical studies since 2000, including nearly 5000 patients in total.
  • Sales analysis by range
  • Growth
  • Operating profit margin
  • R&D / Sales
  • Workforce size
  • Net profit margin
  • STALAIR® investments
  • Sales analysis by market